Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely
Executive SummaryUpcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.
You may also be interested in...
President Trump’s 2019 State of the Union Address broadly touched on the themes of funding childhood cancer research, drug pricing and eliminating HIV.
Roche, through Genentech, returns to the PhRMA fold after leaving the trade group in 2009; Gilead is a first-time member; both are retaining their BIO memberships as well.